Auto-generated from public data. Not the firm's stated position.
Sarsia appears to focus on early-stage investments across biotech and deep tech sectors, with a particular emphasis on companies addressing infrastructure and therapeutic challenges. Recent portfolio activity suggests interest in both life sciences applications, such as anti-fibrosis treatments, and enabling technologies in computing and energy systems, supported by check sizes ranging from €2.0M to €40.0M at pre-seed and seed stages.
Generated 12 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-detected from Sarsia's website.
20 years R&D, IPR and business development experience with multiple turnarounds and international transactions.
PhD pharmacology with 17 years commercializing medical and biotech projects from preclinical to clinical research.
30 years commercialization and M&A experience with deep expertise in corporate and financial management.
Physical oceanography background with diverse career in technology innovation, energy transition and sustainability.
20 years R&D and management experience in instrumentation, telecom and software with Dr.Ing. in applied physics.
14 years VC experience in technology companies with mechanical engineering and financial analyst background.
PhD life sciences with 15 years research and technology transfer expertise from US, France, Sweden and Germany.
20 years in financial and strategic management across offshore, food, real estate and life science sectors.
PhD microbiology with 13 years research and 5 years commercializing biotech and aquaculture projects.
Business development and investment management expert with extensive VC, board and leadership experience.
Focus and check size from the firm's website. Website reachable as of Aug 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.